Tag Archives: hepatitis C

Republican health plan seen as a major setback for hepatitis C Medicaid patients

Amid a growing hepatitis C epidemic, federal austerity measures seen as a setback to infection control.  By Sony Salzman It’s been nearly 20 years since Read More

Posted in Featured Content, General Global Health, Hub Originals, Infectious Disease, Policy & Systems, Social | Also tagged , , , , , , , | Comments closed

Brief Report: The Impact of Ledipasvir/Sofosbuvir on HIV-Positive and HIV-Negative Japanese…

Introduction: Approximately 80% of patients with hemophilia who received nonheated coagulation factor concentrates in the early 1980s were infected with hepatitis C virus (HCV), and approximately 40% of them were infected with HIV.

Posted in General Global Health, HIV/AIDS, Infectious Disease, Journal Watch | Also tagged , , , | Comments closed

New hepatitis C drugs must be affordable worldwide, say campaigners

We must learn from the HIV epidemic and ensure that affordable prices are in place so that the millions with hepatitis C infection can get new drugs that appear to be a cureThere are 185 million people in the world chronically infected with hepatitis C virus, which attacks the liver and can cause liver cancer and cirrhosis. Around 350,000 people die as a result every year. Hepatitis C is blood-borne, may show no symptoms for years and, until recently, its treatment has been far from ideal. Even if you can get interferon and ribavirin, which are not available everywhere, the combination does not work in everybody.

Posted in General Global Health | Also tagged , | Comments closed

Think NoHep this World Hepatitis Day

“Viral hepatitis – a group of infectious diseases known as hepatitis A, B, C, D, and E – affects hundreds of millions of people worldwide, causing acute and chronic liver disease and killing more than 1.4 million people every year, mostly from hepatitis B and hepatitis C. It is estimated that only 5% of people with chronic hepatitis know of their infection, and less that 1% have access to treatment.” – World Health Organization Dr. John W. Ward, Director, Division of Viral Hepatitis CDC’s vision is to eliminate viral hepatitis in the United States and worldwide.  World Hepatitis Day – July 28, 2016 – is an opportunity to highlight the global burden of disease and our efforts to combat viral hepatitis around the world.

Posted in General Global Health, Infectious Disease, Research, Surveillance, Tuberculosis | Also tagged , , , | Comments closed

Hepatitis C Medicines Financially Inaccessible In Many Nations, WHO Study Shows

STAT: Hepatitis C drugs remain unaffordable in many countries, says WHO study “In the latest effort to quantify the burden of expensive medicines, a new study found that the cost of two widely used hepatitis C treatments remains out of reach for people in many poor countries and poses a ‘financial and ethical dilemma’ for…More

Posted in Infectious Disease, Kaiser's Global Health Update | Tagged | Comments closed

A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact

by Elliot Marseille, James G. Kahn In a Perspective accompanying Hill and colleagues, Elliot Marseille and James Kahn compare the history of pricing and availability of ART for HIV with that of the new HCV drugs and discuss strategies for providing treatment in LMIC even in the face of high costs.

Posted in Infectious Disease, Journal Watch | Tagged | Comments closed

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic…

by Swathi Iyengar, Kiu Tay-Teo, Sabine Vogler, Peter Beyer, Stefan Wiktor, Kees de Joncheere, Suzanne Hill Introduction New hepatitis C virus (HCV) medicines have markedly improved treatment efficacy and regimen tolerability. However, their high prices have limited access, prompting wide debate about fair and affordable prices. This study systematically compared the price and affordability of sofosbuvir and ledipasvir/sofosbuvir across 30 countries to assess affordability to health systems and patients. Methods and Findings Published 2015 ex-factory prices for a 12-wk course of treatment were provided by the Pharma Price Information (PPI) service of the Austrian public health institute Gesundheit Österreich GmbH or were obtained from national government or drug reimbursement authorities and recent press releases, where necessary. Prices in Organisation for Economic Co-operation and Development (OECD) member countries and select low- and middle-income countries were converted to US dollars using period average exchange rates and were adjusted for purchasing power parity (PPP).

Posted in Infectious Disease, Journal Watch | Tagged | Comments closed

With biomedical research driven by profit rather than need, MSF examines why innovation fails…

Categories: UncategorizedTags: DNDi, Ebola, hepatitis C, MSF Access Campaign, tuberculosisReport proposes new and focused approaches to developing drugs, diagnostics and vaccines A pharmaceutical company develops a long-awaited drug that represents the last hope for hundreds of thousands of people sick with drug-resistant tuberculosis, but doesn’t register it in any of the countries where the burden of the disease is greatest. While the World Health […](Read more…)

Posted in Ebola, Infectious Disease, Research, Tuberculosis | Also tagged , , , , | Comments closed

Evaluation of two rapid screening assays for detecting hepatitis C antibodies in…

Objective To evaluate the diagnostic accuracy of the OraQuick HCV rapid antibody test from OraSure and the Multisure HCV antibody assay from MP Biomedicals.

Posted in Infectious Disease, Journal Watch, Research | Also tagged | Comments closed

CROI 2016: In the global epidemic of hepatitis C, millions await the cure

Categories: CROI 2016Just as the development of highly active antiretroviral therapy spurred advocacy and finally action to extend treatment to people living with HIV in developing countries, the development of new direct acting antivirals that can cure the vast majority of patients with chronic hepatitis C infection has evoked a call to extend prevention and curative therapy to […](Read more…)

Posted in Aid & Development, Infectious Disease | Also tagged , | Comments closed

Hepatitis C Virus Antibody Testing: Result Availability at Time of Discharge for Emergency…

No abstract available

Posted in HIV/AIDS, Infectious Disease, Journal Watch | Also tagged | Comments closed

Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance…

Background: Infection risks among people who inject drugs (PWID) are widely recognized, but few studies have focused on image and performance enhancing drugs (IPEDs).

Posted in HIV/AIDS, Infectious Disease, Journal Watch, Men's Health | Also tagged , , | Comments closed

Mapping Project Aims To Fill In Hepatitis C Data Gaps

Center for Global Health Policy’s “Science Speaks”: Data mapping highlights realities of global hepatitis C impacts, resources Antigone Barton, senior writer and editor of “Science Speaks,” discusses findings from a report by mapCrowd, a crowdsourcing project launched by Médecins du Monde and the Treatment Action Group that is designed to gather and publicize data on…More

Posted in Infectious Disease, Kaiser's Global Health Update, Mapping, Technology | Also tagged | Comments closed

Data mapping highlights realities of global hepatitis C impacts, resources

Categories: UncategorizedAcross 18 countries the price for a complete package of diagnostic tests for hepatitis C ranges from $67 to nearly ten times that amount, with many of the highest prices in the poorest countries. Of 23 countries contributing information on hepatitis C treatment access, only eight have access to new, safer, more effective treatments. Among […](Read more…)

Posted in Aid, Aid & Development, Infectious Disease, Technology | Also tagged | Comments closed